M. Serhan TAŞDEMİR, Murat AKKUŞ, YUSUF NERGİZ, SELÇUK TÜNİK, İskender KAPLANOĞLU

Atorvastatinin sıçan iskelet kasında oluşturduğu yapısal değişikliklerin ışık mikroskobu ile değerlendirilmesi

Çalışmamızda, bir statin türevi olan atorvastatinin sıçan iskelet kasında oluşturduğu yapısal değişikliklerin ışık mikroskobu düzeyinde incelenmesi ve değerlendirilmesi amaçlandı.40 adet erişkin erkek wistar albino rat; biri kontrol ve dokuzu deney grupları olmak üzere 10 eşit gruba bölündü. . Deneyin başlamasından sonra 5. 10. ve 15. günlerde sakrifiye edilen ratların quadriceps femoris kasları ışık mikroskobunda incelendi. Kontrol grubundan elde edilen kasların histopatolojik incelemelerinde herhangi bir yapısal değişikliğe rastlanmazken, diğer 9 deney grubundan elde edilen kas örneklerinde değişen derecelerde histopatolojik bulgular elde edildi. Genel olarak kaslarda dejenerasyon, kontraksiyon, nekroz, bağdoku artışı, mononükleer hücre infiltrasyonu, kas lifleri arasında vakuoler yapılar ve sentral nükleus belirgin artış göstermekteydi. Çalışmamızda bulgularımız, doz ve zaman arttıkça değişikliklerin belirgin olduğu gözlendi. Atorvastatinin iskelet kaslarında göstermiş olduğu toksik etki ile birlikte, klinik açıdan doz ve zaman baz alınarak, hasta tedavilerine ışık tutacağı kanaatine varıldı.

Evaluation of the atorvastatin-induced structural changes in skeletal muscles of rats by light microscope

In this study we evaluated toxic effects of atorvastatin on the development of muscle necrosis in rats at the light microscopic level .Male, adult 40 Wistar- albino rat used in this study. Rats divided into 10 equal groups as one control, 9 treatment groups. All rats were sacrified after 5th 10th and 15th days of the study.And their quadriceps femoris muscle tissues were examined in light microscopy. In control group there was no histopatologic changes determined on their muscle tissue samples. But on the other hand, in the treatment groups, some histopathologic changes were determined in different degrees. Generally our findings were degenaration, contraction, necrosis, fibrosis in the perimisial area, central nucleus on the muscle tissues. These findings were increased due to the high treatment dose and the long treatment time. Histopathologic changes were increased due to the high treatment dose and the long treatment time. Because of all these reasons, medical doctors will take care about the treatment dose and the long treatment time of the atorvastatin

PDF

___

1. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
2. Shek A and Ferril MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17
3. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95.
4. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-90.
5. Bennett W E, Drake AJ 3rd and Shakir KM. Reversible myopathy after statin therapy in patients with normal creatine kinase levels. Ann Intern Med 2003;138: 436–7.
6. Phillips PS, Haas RH, Bannykh S,et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5
7. Beyer RE. An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 1992;70.390–403.
8. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins On thrombosis and rheology. Atherosclerosis 1998;140:271–80.
9. Maron DJ, Fazio S, Linton MF. Current perspectives On statins. Circulation 2000;101:207-213.
10. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001;24;258-272.
11. Rousseau G, Desrosiers C, Varin F. A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats. Curr Ther Res 1998;59: 666-679.
12. Thelin A, Schedin S, Dallner G. Half-life of ubiquinone-9 in rat tissues. FEBS Lett 1992; 313:118–121.
13. von-Keutz E, Schluter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am J Cardiol 1998;82;11J- 17J.
14. Manfredi G, Spinazzola A, Checcarelli N, Naini A. Assay of mitochondrial ATP synthesis in animal cells. Methods Cell Biol 2001; 65, 139- 141.
15. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J. Pharmacol Exp Ther 1991; 257;1225- 1235.
16. William H, Jeffery W, Amy F, et al. Evalution of ubiquinone Concentration and mitochondrial function relative to cerivastatin- induced skeletal myopathy in rats.Toxicol Applied Pharmacol 2004;194 10-23.
17. Andrew JW,Sıgurd L,Andrew G.Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993;542-549.